Fig. 7

circPSD3 is a novel inhibitor of uPA system. (A) uPAR overexpression in HCC cells examined by qRT-PCR and western blotting. (B) Representative images and quantification of the wound healing assays in uPAR-overexpressing and control HCC cells. Scale bar = 100 μm. (C) Representative images and quantification of the Transwell assays in uPAR-overexpressing and control HCC cells. Scale bar = 100 μm. (D) Wound healed assays in the indicated cells. Scale bar = 100 μm. (E) Transwell assays showing the migration and invasion of the indicated cells. Scale bar = 100 μm. (F) Representative images of H&E and uPAR staining of lung metastatic nodules and quantification of uPAR protein levels in the indicated lung metastasis models. Scale bar (H&E upper) = 1000 μm; Scale bar (H&E lower) = 400 μm; Scale bar (IHC) = 20 μm. (G) Representative images of H&E and uPAR staining of intrahepatic metastatic nodules and quantification of uPAR protein levels in the indicated liver orthotopic implantation models. Scale bar (H&E upper) = 400 μm; Scale bar (H&E lower) = 50 μm; Scale bar (IHC) = 20 μm. Data are shown as the mean ± SD. Statistical analyses were performed using unpaired Student’s t-tests (NS, no statistical significance; **p < 0.01; ***p < 0.001; ****p < 0.0001). circPSD3, circRNA pleckstrin and Sect. 7 domain containing 3; HCC, hepatocellular carcinoma; H&E, haematoxylin and eosin; qRT-PCR, quantitative real-time PCR; uPA, urokinase-type plasminogen activator; uPAR, uPA receptor